CytoAgents >>
cytoagents.com
Actively hiring
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$13.1M
6 rounds on record
Latest round
$7M
Venture round · May 2023 · 3 yr ago
Team
2
US Form 5500 (plan participants) · Dec 2025 · -60% in a year
Grants
$7M
4 grants · CORDIS
Backers
1
Boston Harbor Angels
The money's age
Long since its last round
41 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Sep 22, 2025
Won a grant $1.3M · CORDIS
Sep 20, 2024
Won a grant $2M · CORDIS
May 3, 2023
Raised a round Venture round $7M · SEC Form D
Jul 30, 2021
Raised a round Venture round $6.1M · SEC Form D
Mar 6, 2021
Won a grant $2M · CORDIS
May 8, 2020
Won a grant $1.7M · CORDIS
2018
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Grant | Sep 2025 | $1.3M | — | CORDIS |
| Grant | Sep 2024 | $2M | — | CORDIS |
| Venture round | May 2023 | $7M | — | SEC Form D |
| Venture round | Jul 2021 | $6.1M | — | SEC Form D |
| Grant | Mar 2021 | $2M | — | CORDIS |
| Grant | May 2020 | $1.7M | — | CORDIS |
Registers and programsofficial lists and records that name the company
| Legal entity | CytoAgents, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Teresa WhalenExecutive Officer, DirectorSEC Form D
Roy PriebExecutive OfficerSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Boston Harbor Angels Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
PsiThera is advancing programs across multiple targets from the TNF superfamily and beyond, where no oral therapies currently exist.
Biossil is an AI native biopharma company based in Toronto. It is advancing late-stage programs in life-threatening indications with urgent…
Discovering, Developing and Commercializing the Next Generation of Selective Cytokine Therapeutics. We believe that cytokine therapeutics…
Precision-engineered, bi-specific cytokines to treat autoimmune and inflammatory diseases. Highly versatile protein-design platform to…
Biotia is advancing infectious disease diagnostics for patients managing challenging infections. Learn more about our work.
Alpheus is advancing a new therapeutic approach designed to improve outcomes while reducing treatment burden for patients and families.
News
CytoAgents Expands Scientific Advisory Board Appointing Dr. Michael Wechsler and Dr. Johann Gudjonsson to Guide Pipeline Expansion
PITTSBURGH-(BUSINESS WIRE)-CytoAgents, Inc., a clinical-stage biotechnology company at the forefront of immunologic research, today announced the addition of two distinguished scientists to its Scientific Advisory Board (SAB): Dr. Michael Wechsler, and Dr
Read more
Report
CytoAgents Expands Scientific Advisory Board Appointing Dr. Michael Wechsler and Dr. Johann Gudjonsson to Guide Pipeline Expansion
PITTSBURGH, May 20, 2026--CytoAgents expanded its Scientific Advisory Board with the appointments of Dr. Michael Wechsler and Dr. Johann Gudjonsson to support pipeline growth.
Read more
Report
CytoAgents Expands Scientific Advisory Board Appointing Dr. Michael Wechsler and Dr. Johann Gudjonsson to Guide Pipeline Expansion - AOL
Read more
Report
CytoAgents Expands Scientific Advisory Board Appointing Dr. Michael Wechsler and Dr. Johann Gudjonsson to Guide Pipeline Expansion
Read more
Report
CytoAgents Appoints Dr. Johannes Wolff as Chief Medical Officer and Michael Howell as Chief Scientific Officer
PITTSBURGH-(BUSINESS WIRE)-CytoAgents, Inc. a clinical-stage biotechnology company developing CTO1681, a novel, steroid-sparing inhibitor of prostaglandin-mediated inflammation, announced today the appointment of Dr. Johannes Wolff, MD, PhD, as Chief Medi
Read more
Report
CytoAgents to Present New CTO1681 Data at the ESMO Immuno-Oncology Congress 2025
PITTSBURGH-(BUSINESS WIRE)-CytoAgents, Inc., a clinical-stage biotechnology company developing CTO1681, a novel, steroid-sparing inhibitor of prostaglandin-mediated inflammation announced today that data from two of its Investigational New Drug (IND) appl
Read more
Report
CytoAgents Announces Poster Presentation of New CTO1681 Clinical Data at the 67th American Society of Hematology Annual Meeting
PITTSBURGH-(BUSINESS WIRE)-CytoAgents, Inc., a clinical-stage biotechnology company developing CTO1681, a novel, steroid sparing inhibitor of prostaglandin mediated inflammation, announced today that preliminary safety data from its Phase 1b/2a clinical t
Read more
Report
CytoAgents Announces Poster Presentation of New CTO1681 Clinical Data at the 67th American Society of Hematology Annual Meeting
PITTSBURGH, December 02, 2025--CytoAgents announced a poster presentation of new CTO1681 clinical data at the 67th American Society of Hematology Annual Meeting.
Read more
Report
Bolstering CAR-T therapies by tackling CRS, with Teresa Whalen
Providing cures for cancers previously thought uncurable, CAR-T therapies have been a bright success story for cell therapy. But they're not without their problems: in addition to expensive infrastructure challenges, CAR-T therapies also have to deal with
Read more
Report
CytoAgents Receives Fourth Grant From National Institutes of Health to Advance Research on Cytokine Release Syndrome
PITTSBURGH-(BUSINESS WIRE)-CytoAgents, Inc., a clinical-stage biotechnology company developing a safe and effective preventative treatment for cytokine release syndrome (CRS) and the neurotoxicity immune effector cell-associated neurotoxicity syndrome (IC
Read more
Report
Show more news
People
Teresa Whalen
Executive Officer, Director
Roy Prieb
Executive Officer
Catherine Mott
Director
Anthony McCarley
Director
John Friedman
Director
Stanley Marks
Director
Robert Ferris
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Pittsburgh
United States
HQ
50-200 est. staff
100 S. Commons Suite 102, Pittsburgh, PA 15212